Company intelligence / Profile preview

Walking Fish Therapeutics

South San Francisco, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company developed a platform to engineer B cells to function as protein factories and immune modulators. Their first program, WFX-001, was aimed at Fabry disease. The company closed down in May 2024 after a lead investor backed out of a critical Series B funding round.

Therapeutic areas: OtherOncologyImmunologyRare Diseases
Modalities: B cell therapiesengineered B cellscell therapy
Industry: Biotech

Drug pipeline

3 assets

WFX-001

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Walking Fish Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Walking Fish Therapeutics.

Explore the full profile